From 2022:

Chandraganti S, Sams C, Sahoo S, Feng B, O’Connell I, Li L, Nepal S, Pulukuri S, Bakhle K, Thiru P, Simian C, Bell GW, Jolly MK, Dongre A. CD4+ T-cells sensitize quasi-mesenchymal breast tumors lacking CD73 to anti-CTLA4 immune checkpoint blockade therapy. bioRxiv., 2025 May 13. doi.org/10.1101/2025.05.12.653467

O’Connell I and Dongre A. Immunotherapy for Breast Cancer: Lessons from Epithelial-Mesenchymal Transition., Mol Diagn Ther. 27, 433–444, 2023.

Dongre A*, Ortiz-Cuaran S, and Korkaya H. Editorial: The role of the EMT program in regulating the immune response in carcinoma., Front in Immunol, 2022, 940164. * co-corresponding

Ferrao P, Dongre A, Jolly MK, Jayachandran A and Thompson R. Editorial: Cancer Plasticity, the Microenvironment and Therapy Resistance: Implications for Immunity and New Treatment Strategies. Volume II. Frontiers in Oncology – Special Research Topic, 2023

 Hu D, Lyu X, Li Z, Ekambaram P, Dongre A, Freeman T, Joy M, Atkinson JM, Brown DD, Cai Z, Carleton NM, Butterfield H, Little J, Sperinde J, Huang W, Joensuu H, Srinivasan A, Pogue-Geile KL, Wang Y, Feng H, Eli LD, Lalani AS, Zou J, Tseng GC, Bruno TC, Lee AV, Oesterreich S, Wolmark N, Allegra CJ, Jacobs SA, McAllister-Lucas LM,, and Lucas PC. The truncated HER2 species, p95HER2, drives immune suppression in HER2+ breast cancer and thereby limits trastuzumab deruxtecan efficacy. Nature Cancer, 2025 Jul;6(7):1202-1222

Prior to 2022:

Dongre A, Rashidian M, Eaton NE, Reinhardt F, Thiru P, Zagorulya M, Nepal S, Banaz T, Martner AM, Spranger S and Weinberg RA. Direct and Indirect regulators of Epithelial-to-Mesenchymal Transition induced Immunosuppression in Breast Carcinomas. Cancer Discovery. 2021;11:1–20. doi: 10.1158/2159-8290.CD-20-0603.

Dongre A, Weinberg RA. New insights into the mechanisms of epithelial-mesenchymal transition and implications for cancer. Nat Rev Mol Cell Biol. 2019 Feb;20(2):69-84. doi: 10.1038/s41580-018-0080-4. Review.

Dongre A, Rashidian M, Reinhardt F, Bagnato A, Keckesova Z, Ploegh HL, Weinberg RA. Epithelial-to-Mesenchymal Transition Contributes to Immunosuppression in Breast Carcinomas. Cancer Res. 2017 Aug 1;77(15):3982-3989. doi: 10.1158/0008-5472.CAN-16-3292. Epub 2017 Apr 20. (Cover Page Article)

Dongre A, Weinberg RA. Leveraging immunochemotherapy for treating pancreatic cancer. Cell Res. 2021. 31 (12), 1228-1229.

Dongre A, Surampudi L, Lawlor RG, Fauq AH, Miele L, Golde TE, Minter LM, Osborne BA. Non-Canonical Notch Signaling Drives Activation and Differentiation of Peripheral CD4(+) T Cells. Front Immunol. 2014 Feb 12;5:54

Rashidian M, LaFleur MW, Verschoor VL, Dongre A, Zhang Y, Nguyen TH, Kolifrath S, Aref AR, Lau CJ, Paweletz CP, Bu X, Freeman GJ, Barrasa MI, Weinberg RA, Sharpe AH, Ploegh HL. Immuno-PET identifies the myeloid compartment as a key contributor to the outcome of the antitumor response under PD-1 blockade. Proc Natl Acad Sci U S A. 2019 Aug 20;116(34):16971-16980. doi: 10.1073/pnas.1905005116. Epub 2019 Aug 2.

Rashidian M, Ingram JR, Dougan M, Dongre A, Whang KA, LeGall C, Cragnolini JJ, Bierie B, Gostissa M, Gorman J, Grotenbreg GM, Bhan A, Weinberg RA, Ploegh HL. Predicting the response to CTLA-4 blockade by longitudinal noninvasive monitoring of CD8 T cells. J Exp Med. 2017 Aug 7;214(8):2243-2255. doi: 10.1084/jem.20161950. Epub 2017 Jun 30.

Castaño Z, San Juan BP, Spiegel A, Pant A, DeCristo MJ, Laszewski T, Ubellacker JM, Janssen SR, Dongre A, Reinhardt F, Henderson A, Del Rio AG, Gifford AM, Herbert ZT, Hutchinson JN, Weinberg RA, Chaffer CL, McAllister SS. IL-1β inflammatory response driven by primary breast cancer prevents metastasis-initiating cell colonization. Nat Cell Biol. 2018 Sep;20(9):1084-1097. doi: 10.1038/s41556-018-0173-5. Epub 2018 Aug 27.

Wang H, Xiang D, Liu B, He A, Randle HJ, Zhang KX, Dongre A, Sachs N, Clark AP, Tao L, Chen Q, Botchkarev VV Jr, Xie Y, Dai N, Clevers H, Li Z, Livingston DM. Inadequate DNA Damage Repair Promotes Mammary Transdifferentiation, Leading to BRCA1 Breast Cancer. Cell. 2019 Jun 27;178(1):135-151.e19. doi: 10.1016/j.cell.2019.06.002.

De Cock JM, Shibue T, Dongre A, Keckesova Z, Reinhardt F, Weinberg RA. Inflammation triggers Zeb1-dependent escape from tumor latency. Cancer Res. 2016 Dec 1;76(23):6778-6784.

Roderick JE, Gonzalez-Perez G, Kuksin CA, Dongre A, Roberts ER, Srinivasan J, Andrzejewski C Jr, Fauq AH, Golde TE, Miele L, Minter LM. Therapeutic targeting of NOTCH signaling ameliorates immune-mediated bone marrow failure of aplastic anemia. J Exp Med. 2013 Jul 1;210(7):1311-29.

Ortiz-Cuaran S, Swalduz A, Jean-Philippe Foy, Marteau S, Morel AP, Fauvet F, Boussageon M, Leonce C, Dongre A, Vanbervliet B, Robert M, Mourksi N, Pommier RM, Albaret AM, De Souza G, Hofman V, Gadot N, Attignon V, Audoynaud C, Auclair J, Bouquet F, Caux CM, Wang Q, Perol M, Caux C, Hofman P, Lantuejoul S, Puisieux A, Saintigny P. Epithelial-to-mesenchymal transition promotes immune escape by inducing CD70 in non-small lung cancer. European Journal of Cancer. 2022 169, 106-122

Kumar SV, Pota T, Peri D, Dongre AD, Rao BJ. Low energy electron induced damage to plasmid DNA pQE30. J Chem Phys. 2012 Jul 28;137(4):045101.